Related Experiment Video
Updated: Jan 8, 2026
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Selective genome editing of amplified oncogenes triggers immunogenic cell death and tumor remodeling
A Nieto-Sanchez1, M Martinez-Lage1, P Puig-Serra1
1Molecular Cytogenetics and Genome Editing Unit, Human Cancer Genetics Programme, Spanish National Cancer Centre (CNIO), Madrid, Spain.
Abstract:
Oncogene amplifications fuel some of the most lethal, therapy‑refractory cancers, yet remain clinically untargeted. We report a single‑guide CRISPR/Cas9 strategy that converts the sheer copy‑number excess of oncogene amplicons into an Achilles' heel. A solitary intronic double‑strand break is innocuous in diploid genomes but collapses oncogene amplification‑positive cells across neuroblastoma, small‑cell lung and colorectal carcinoma models, driving > 90% loss of viability, G₂/M blockade and catastrophic DNA‑damage signalling. Amplified‑locus cleavage rewires transcription toward cell death activation, necroptosis and cGAS-STING-mediated immunogenic cell death, enabling dendritic‑cell cross‑priming and T‑cell activation and proliferation. In xenografts, delivery of the intronic sgRNA shrinks tumours by 90%, prolongs survival and remodels the innate tumour microenvironment. Deep sequencing confirms negligible off‑target editing, and combination with doxorubicin achieves supra‑additive killing. These findings establish amplification density, not sequence content, as a tractable, tumour‑exclusive target and unveil a dual‑action platform that is simultaneously cytotoxic and immunostimulatory. Editing of tumor amplifications therefore offers a blueprint for translating copy‑number aberrations into precision genome‑editing therapies for treatment‑resistant cancers.
Insights
CRISPR gene editing targets oncogene amplifications, common in lethal cancers, by inducing DNA breaks. This approach causes cancer cell death and triggers an immune response, shrinking tumors and improving survival.
Area of Science:
- Genetics and Genomics
- Cancer Biology
- Immunotherapy
Background:
- Oncogene amplifications are key drivers of therapy-refractory cancers but lack targeted therapies.
- Current treatments often fail against cancers with high oncogene copy numbers.
Purpose of the Study:
- To develop a novel CRISPR/Cas9 strategy targeting oncogene amplification density, not sequence.
- To evaluate the efficacy of this strategy in preclinical cancer models.
Main Methods:
- Utilized a single-guide CRISPR/Cas9 system to induce a double-strand break within an intronic region of amplified oncogenes.
- Assessed cell viability, cell cycle arrest, DNA damage response, and cell death pathways (necroptosis, cGAS-STING).
- Evaluated anti-tumor efficacy in xenograft models and analyzed immune microenvironment changes and off-target editing via deep sequencing.
Main Results:
- A single intronic break in amplified oncogenes led to >90% loss of viability across neuroblastoma, SCLC, and colorectal cancer models.
- Cleavage triggered G2/M arrest, catastrophic DNA damage, necroptosis, and cGAS-STING-mediated immunogenic cell death.
- Tumor xenografts showed 90% shrinkage, prolonged survival, and enhanced T-cell responses with minimal off-target effects.
Conclusions:
- Oncogene amplification density is a viable, tumor-exclusive target for genome editing.
- This CRISPR strategy offers a dual-action platform, being both cytotoxic and immunostimulatory.
- This approach provides a blueprint for precision genome-editing therapies against treatment-resistant cancers.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:38Mitogens and the Cell Cycle